title: [Anti-epidermal growth factor receptor monoclonal antibodies induced adverse events].
abstract: Cetuximab and panitumumab, both anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MAb), have demonstrated clinical activity in patients with colorectal cancer. They are well tolerated, but they involve various adverse events that are rare among cytotoxic agents. Typical adverse events associated with anti-EGFR MAbs include infusion reaction, skin toxicity, lung toxicity, and hypomagnesemia. It is necessary to recognize and manage adverse events promptly to continue treatments without drug discontinuation. This report details the adverse events and their management with anti-EGFR MAbs use.
authors.affiliation: Department of Medical Oncology, KKR Sapporo Medical Center Tonan Hospital, Chuo-ku, Sapporo, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Tsuji
authors.forename: Takahiro
authors.initials: T
authors.lastname: Kogawa
authors.forename: Masakazu
authors.initials: M
authors.lastname: Abe
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology; D004342:Drug Hypersensitivity / Q000276:immunology; D066246:ErbB Receptors / Q000276:immunology*; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced; D008275:Magnesium Deficiency / Q000139:chemically induced; D012871:Skin Diseases / Q000139:chemically induced
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D066246:ErbB Receptors